SY-707, previously known as CT-707, is a multiple kinase inhibitor against ALK, FAK and IFG1R, which was approved for the treatment of ALK-positive patients with NSCLC in 2016 (NCT02695550). This evidence concerns the gene PTK2 and non-small cell lung carcinoma.